QLGN QUALIGEN THERAPEUTICS INC Management Changes 8-K Filing 2024 - Management Changes Qualigen Therapeutics announced the immediate resignations of CEO Michael Poirier and CFO Christopher Lotz due to disagreements about the company's direction, and appointed Kevin Richardson II as Interim CEO and CFO, with a consulting fee of $4,500 per week.Get access to all SEC 8-K filings of the QUALIGEN THERAPEUTICS INC